$AVLN News

Syndax Pharmaceuticals Stock Plunges. A Failed Trial Deals Blow to Growth Plans.

Raymond James Initiates Coverage On Avalyn Pharma with Outperform Rating, Announces Price Target of $60

Avalyn Pharma (AVLN) Following AP02 Phase 1 Data Is Its Valuation Too Pricey

Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile

Avalyn Pharma Says Respiratory Research Publishes Detailed Results From Two Phase 1 Clinical Trials Of AP02 In Healthy Volunteers And Patients With IPF, Validating Inhaled Antifibrotic Approach

Avalyn Pharma Inc. (AVLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis

Avalyn Pharma Reports New Data Showing Predicted Aerosol Distribution Of AP01 And Survey Data Highlighting Patient Perspectives On Participation In Clinical Studies For Idiopathic Pulmonary Fibrosis

Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026

Morgan Stanley Maintains Overweight on Avalyn Pharma, Raises Price Target to $57

Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Avalyn Pharma Q2 EPS $(0.65) Misses $(0.53) Estimate

Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis

Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead

Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights

Assessing Avalyn Pharma (AVLN) Valuation As Investors React To Recent Share Price Moves

Avalyn to Participate in the Jefferies Global Healthcare Conference

Evercore ISI Group Initiates Coverage On Avalyn Pharma with Outperform Rating, Announces Price Target of $51

Guggenheim Initiates Coverage On Avalyn Pharma with Buy Rating, Announces Price Target of $80